FDA
-
-
-
-
-
-
-
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
-
-
-
-
-
-
-
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
-
-
-
-
-
-
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
-
-
-
-
-
-
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™
-
-
-
-
-
-
-
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Announces FDA Acceptance of BLA for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

